Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.

Here we report a unique situation in which an early and synchronized Epstein-Barr virus (EBV) reactivation was induced by a 6-day course of treatment with a humanized CD3-specific monoclonal antibody in patients with recent onset of type 1 diabetes. The virologic and immunologic analysis demonstrate...

Full description

Bibliographic Details
Main Authors:	Keymeulen, B, Candon, S, Fafi-Kremer, S, Ziegler, A, Leruez-Ville, M, Mathieu, C, Vandemeulebroucke, E, Walter, M, Crenier, L, Thervet, E, Legendre, C, Pierard, D, Hale, G, Waldmann, H, Bach, J, Seigneurin, J, Pipeleers, D, Chatenoud, L
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
by: Keymeulen, B, et al.
Published: (2005)

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
by: Keymeulen, B, et al.
Published: (2010)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
by: Hale, G, et al.
Published: (1998)

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.
by: Hale, G, et al.
Published: (2010)

Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
by: Alkemade, G, et al.
Published: (2011)

Tolerance induction by monoclonal CD3 antibodies is dependent on indoleamine 2,3 dioxygenase (IDO)
by: Kuhn, C, et al.
Published: (2012)

EPSTEIN-BARR VIRUS: CAUSES, CONSEQUENCES, DIAGNOSIS AND TREATMENT OF EPSTEIN-BARR VIRUS IN HUMAN
by: Koprivica Marko
Published: (2024-04-01)

Infection with Epstein-Barr virus.
by: Warrell, D, et al.
Published: (1978)

Infection with Epstein-Barr virus.
by: Warrell, D, et al.
Published: (1978)

??????? ??? ????? ????? ???????- ???Epstein-Barr virus(EBV) ????? ?????? ????? ????? ?? ?????? ?? ???
by: ستار عبود فارس, et al.
Published: (2019-05-01)

??????? ??? ????? ????? ???????- ???Epstein-Barr virus(EBV) ????? ?????? ????? ????? ?? ?????? ?? ???
by: ستار عبود فارس, et al.
Published: (2019-05-01)

Resurrecting Epstein–Barr Virus
by: Roberto Paganelli
Published: (2022-07-01)

Epstein-Barr virus and skin
by: Martin Sangueza-Acosta, et al.
Published: (2018-12-01)

The epstein-Barr virus and the pathogenesis of lymphoma
by: Vockerodt, M., et al.
Published: (2015)

Soro-epidemiologia do virus de Epstein-Barr (VEB) The seroepidemiology of the Epstein-Barr vírus (EBV)
by: Claudio Sergio Pannuti
Published: (1981-02-01)

Potential Cellular Functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus
by: Danielle Westhoff Smith, et al.
Published: (2013-01-01)

Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants.
by: Wallace, L, et al.
Published: (1981)

Atomic structure of the Epstein-Barr virus portal
by: Cristina Machón, et al.
Published: (2019-08-01)

Epstein-barr virus specific immunogen
by: Seow, Heng Fong, et al.
Published: (2011)

Vaccination against the Epstein-Barr virus
by: Rühl, J, et al.
Published: (2020)

Macular Amyloidosis and Epstein-Barr Virus
by: Yalda Nahidi, et al.
Published: (2016-01-01)

Epstein-Barr Virus Neurologic Complications
by: J. Gordon Millichap
Published: (2015-12-01)

Multiple Sclerosis and Epstein-Barr Virus
by: Ruth Ann Marrie, et al.
Published: (2002-01-01)

The pathology of epstein-barr virus lymphoproliferations
by: Stefan D. Dojcinov, et al.
Published: (2019-06-01)

Epstein–Barr Virus History and Pathogenesis
by: Hui Yu, et al.
Published: (2023-03-01)

Novel Therapeutics for Epstein–Barr Virus
by: Graciela Andrei, et al.
Published: (2019-03-01)

Epstein-Barr Virus and Neurological Diseases
by: Nan Zhang, et al.
Published: (2022-01-01)

Is Epstein-Barr virus associated with pterygium?
by: Kelishadi M, et al.
Published: (2014-07-01)

Epstein-Barr Virus-induced Jaundice
by: Jessica Herold, et al.
Published: (2020-02-01)

Epstein–Barr Virus and Hemophagocytic Lymphohistiocytosis
by: Rebecca A. Marsh
Published: (2018-01-01)

The Epstein Barr virus circRNAome.
by: Nathan Ungerleider, et al.
Published: (2018-08-01)

Epstein-Barr Virus and Multiple Sclerosis
by: Gunnar Houen, et al.
Published: (2020-12-01)

Plasma Epstein-Barr Virus DNA load for diagnostic and prognostic assessment in intestinal Epstein-Barr Virus infection
by: Chunxiang Ma, et al.
Published: (2025-01-01)

Epstein-Barr Virus Encephalitis in an Immunocompetent Child: A Case Report and Management of Epstein-Barr Virus Encephalitis
by: Gulsen Akkoc, et al.
Published: (2016-01-01)

Clinical significance of anti-Epstein–Barr virus antibodies in systemic chronic active Epstein–Barr virus disease
by: Miwako Nishio, et al.
Published: (2024-01-01)

Evaluation of plasma Epstein–Barr virus DNA as a biomarker for Epstein–Barr virus–associated Hodgkin lymphoma
by: Masuma Khatun Usha, et al.
Published: (2021-10-01)

Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial　tissues of rheumatoid arthritis.
by: Shotaro Masuoka, et al.
Published: (2018-01-01)

Three-dimensional Models of the Nasopharynx for the Study of Epstein-Barr Virus Infection
by: Phillip Ziegler, et al.
Published: (2022-03-01)

FACTORS AND MECHANISMS OF IMMUNOSUPRESSION IN EPSTEIN-BARR VIRUS INFECTION
by: L. U. Barycheva, et al.
Published: (2015-08-01)

Acute Epstein-Barr virus infection presenting as Guillain-Barre syndrome
by: Lindsey A. Wallace, et al.
Published: (2021-01-01)